These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

11350 related articles for article (PubMed ID: 11235990)

  • 1. Potentiation of antitumor effect of NKT cell ligand, alpha-galactosylceramide by combination with IL-12 on lung metastasis of malignant melanoma cells.
    Nakui M; Ohta A; Sekimoto M; Sato M; Iwakabe K; Yahata T; Kitamura H; Koda T; Kawano T; Makuuchi H; Taniguchi M; Nishimura T
    Clin Exp Metastasis; 2000; 18(2):147-53. PubMed ID: 11235990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced suppression of pulmonary metastasis of malignant melanoma cells by combined administration of alpha-galactosylceramide and interleukin-18.
    Nishio S; Yamada N; Ohyama H; Yamanegi K; Nakasho K; Hata M; Nakamura Y; Fukunaga S; Futani H; Yoshiya S; Ueda H; Taniguchi M; Okamura H; Terada N
    Cancer Sci; 2008 Jan; 99(1):113-20. PubMed ID: 17949451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The natural killer T (NKT) cell ligand alpha-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells.
    Kitamura H; Iwakabe K; Yahata T; Nishimura S; Ohta A; Ohmi Y; Sato M; Takeda K; Okumura K; Van Kaer L; Kawano T; Taniguchi M; Nishimura T
    J Exp Med; 1999 Apr; 189(7):1121-8. PubMed ID: 10190903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural killer T cell ligand alpha-galactosylceramide inhibited lymph node metastasis of highly metastatic melanoma cells.
    Nakui M; Iwakabe K; Ohta A; Sekimoto M; Sato M; Makuuchi H; Kawano T; Taniguchi M; Nishimura T
    Jpn J Cancer Res; 1999 Aug; 90(8):801-4. PubMed ID: 10543249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sequential production of interferon-gamma by NK1.1(+) T cells and natural killer cells is essential for the antimetastatic effect of alpha-galactosylceramide.
    Smyth MJ; Crowe NY; Pellicci DG; Kyparissoudis K; Kelly JM; Takeda K; Yagita H; Godfrey DI
    Blood; 2002 Feb; 99(4):1259-66. PubMed ID: 11830474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NKT cells act as regulatory cells rather than killer cells during activation of NK cell-mediated cytotoxicity by alpha-galactosylceramide in vivo.
    Chamoto K; Takeshima T; Kosaka A; Tsuji T; Matsuzaki J; Togashi Y; Ikeda H; Nishimura T
    Immunol Lett; 2004 Aug; 95(1):5-11. PubMed ID: 15325792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. α-Galactosylceramide and peptide-based nano-vaccine synergistically induced a strong tumor suppressive effect in melanoma.
    Sainz V; Moura LIF; Peres C; Matos AI; Viana AS; Wagner AM; Vela Ramirez JE; S Barata T; Gaspar M; Brocchini S; Zloh M; Peppas NA; Satchi-Fainaro R; F Florindo H
    Acta Biomater; 2018 Aug; 76():193-207. PubMed ID: 29940370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms of the antimetastatic effect in the liver and of the hepatocyte injury induced by alpha-galactosylceramide in mice.
    Nakagawa R; Nagafune I; Tazunoki Y; Ehara H; Tomura H; Iijima R; Motoki K; Kamishohara M; Seki S
    J Immunol; 2001 Jun; 166(11):6578-84. PubMed ID: 11359810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interleukin-2 gene transfer potentiates the alpha-galactosylceramide-stimulated antitumor effect by the induction of TRAIL in NKT and NK cells in mouse models of subcutaneous and metastatic carcinoma.
    Nishihori Y; Kato K; Tanaka M; Okamoto T; Hagiwara S; Araki N; Kogawa K; Kuribayashi K; Nakamura K; Niitsu Y
    Cancer Biol Ther; 2009 Sep; 8(18):1763-70. PubMed ID: 19901518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Age-associated augmentation of the synthetic ligand- mediated function of mouse NK1.1 ag(+) T cells: their cytokine production and hepatotoxicity in vivo and in vitro.
    Inui T; Nakagawa R; Ohkura S; Habu Y; Koike Y; Motoki K; Kuranaga N; Fukasawa M; Shinomiya N; Seki S
    J Immunol; 2002 Dec; 169(11):6127-32. PubMed ID: 12444115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Essential role of bystander cytotoxic CD122+CD8+ T cells for the antitumor immunity induced in the liver of mice by alpha-galactosylceramide.
    Nakagawa R; Inui T; Nagafune I; Tazunoki Y; Motoki K; Yamauchi A; Hirashima M; Habu Y; Nakashima H; Seki S
    J Immunol; 2004 Jun; 172(11):6550-7. PubMed ID: 15153469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Critical contribution of IFN-gamma and NK cells, but not perforin-mediated cytotoxicity, to anti-metastatic effect of alpha-galactosylceramide.
    Hayakawa Y; Takeda K; Yagita H; Kakuta S; Iwakura Y; Van Kaer L; Saiki I; Okumura K
    Eur J Immunol; 2001 Jun; 31(6):1720-7. PubMed ID: 11385616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natural killer T cell ligand alpha-galactosylceramide protects against gut ischemia reperfusion-induced organ injury in mice.
    Zhang J; Bi J; Ren Y; Du Z; Li T; Li Q; Ke M; Dong J; Lv Y; Wu R
    Cytokine; 2018 Nov; 111():237-245. PubMed ID: 30195979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natural killer T cells from interleukin-4-deficient mice are defective in early interferon-gamma production in response to alpha-galactosylceramide.
    Togashi Y; Chamoto K; Wakita D; Tsutsumi N; Iwakura Y; Matsubara N; Kitamura H; Nishimura T
    Cancer Sci; 2007 May; 98(5):721-5. PubMed ID: 17359285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancement of the synthetic ligand-mediated function of liver NK1.1Ag+ T cells in mice by interleukin-12 pretreatment.
    Habu Y; Uchida T; Inui T; Nakashima H; Fukasawa M; Seki S
    Immunology; 2004 Sep; 113(1):35-43. PubMed ID: 15312134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential regulation of Th1 and Th2 functions of NKT cells by CD28 and CD40 costimulatory pathways.
    Hayakawa Y; Takeda K; Yagita H; Van Kaer L; Saiki I; Okumura K
    J Immunol; 2001 May; 166(10):6012-8. PubMed ID: 11342617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of γδ T cells in α-galactosylceramide-mediated immunity.
    Paget C; Chow MT; Duret H; Mattarollo SR; Smyth MJ
    J Immunol; 2012 Apr; 188(8):3928-39. PubMed ID: 22412194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation by Src homology 2 domain-containing protein tyrosine phosphatase substrate-1 of alpha-galactosylceramide-induced antimetastatic activity and Th1 and Th2 responses of NKT cells.
    Okajo J; Kaneko Y; Murata Y; Tomizawa T; Okuzawa C; Saito Y; Kaneko Y; Ishikawa-Sekigami T; Okazawa H; Ohnishi H; Matozaki T; Nojima Y
    J Immunol; 2007 May; 178(10):6164-72. PubMed ID: 17475843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyporesponsiveness to natural killer T-cell ligand alpha-galactosylceramide in cancer-bearing state mediated by CD11b+ Gr-1+ cells producing nitric oxide.
    Yanagisawa K; Exley MA; Jiang X; Ohkochi N; Taniguchi M; Seino K
    Cancer Res; 2006 Dec; 66(23):11441-6. PubMed ID: 17145891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prolonged IFN-gamma-producing NKT response induced with alpha-galactosylceramide-loaded DCs.
    Fujii S; Shimizu K; Kronenberg M; Steinman RM
    Nat Immunol; 2002 Sep; 3(9):867-74. PubMed ID: 12154358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 568.